SRF expression in tumour tissues from prostate cancer patients has been extensively characterised by our group, showing that elevated nuclear SRF expression occurs early on during prostate cancer progression [13] and is associated with castrate resistance [7], shorter survival from diagnosis [12] and decreased response to docetaxel [14]. This evidence concerns the gene SRF and prostate carcinoma.